Amphastar gets FDA approval for succinylcholine chloride injection
RANCHO CUCAMONGA, Calif. — Amphastar Pharmaceuticals announced that the U.S. Food and Drug Administration has approved its Abbreviated New Drug Application for Succinylcholine Chloride Injection USP, 200 mg/10 mL (20 mg/mL) Multiple-Dose Vial. Amphastar’s newly approved drug product was determined by the FDA to be therapeutically equivalent to Quelicin (succinylcholine chloride injection USP, 200 mg/10
